Impact of T Cell Dose on Outcome of T Cell-Replete HLA-Matched Allogeneic Peripheral Blood Stem Cell Transplantation.
Publication/Presentation Date
9-1-2019
Abstract
Data on whether the T cell dose of allogeneic peripheral blood stem cell (PBSC) products influences transplantation outcomes are conflicting. Using the Center for International Blood and Marrow Transplant Research database, we identified 2736 adult patients who underwent first allogeneic PBSC transplantation for acute leukemia or myelodysplastic syndrome between 2008 and 2014 using an HLA-matched sibling donor (MSD) or an 8/8-matched unrelated donor (MUD). We excluded ex vivo and in vivo T cell-depleted transplantations. Correlative analysis was performed between CD3
Volume
25
Issue
9
First Page
1875
Last Page
1883
ISSN
1523-6536
Published In/Presented At
Saad, A., Lamb, L., Wang, T., Hemmer, M. T., Spellman, S., Couriel, D., Alousi, A., Pidala, J., Abdel-Azim, H., Agrawal, V., Aljurf, M., Beitinjaneh, A. M., Bhatt, V. R., Buchbinder, D., Byrne, M., Cahn, J. Y., Cairo, M., Castillo, P., Chhabra, S., Diaz, M. A., … Hashmi, S. (2019). Impact of T Cell Dose on Outcome of T Cell-Replete HLA-Matched Allogeneic Peripheral Blood Stem Cell Transplantation. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 25(9), 1875–1883. https://doi.org/10.1016/j.bbmt.2019.05.007
Disciplines
Medicine and Health Sciences
PubMedID
31085303
Department(s)
Department of Medicine, Lehigh Valley Topper Cancer Institute
Document Type
Article